Federal Register / Vol. 60, No. 246 / Friday, December 22, 1995 / Notices 66553

Research at DOE Sites: Savannah River Site

Health Effect Subcommittee (SRS).

Times and Dates: 9 a.m.–5 p.m., January

11, 1996; 9 a.m.–12 noon, January 12, 1996.

Place: Hilton—The De Soto, 15 East Liberty

Street, Savannah, Georgia 31401, telephone

912/232–9000, FAX 912/232–6018.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 75 people.

Background: Under a Memorandum of

Understanding (MOU) signed in December

1990 with DOE, the Department of Health

and Human Services (HHS) has been given

the responsibility and resources for

conducting analytic epidemiologic

investigations of residents of communities in

the vicinity of DOE facilities, workers at DOE

facilities, and other persons potentially

exposed to radiation or to potential hazards

from non-nuclear energy production use.

HHS delegated program responsibility to

CDC.

In addition, an MOU was signed in October

1990 and renewed in November 1992

between ATSDR and DOE. The MOU

delineates the responsibilities and

procedures for ATSDR’s public health

activities at DOE sites required under

sections 104, 105, 107, and 120 of the

Comprehensive Environmental Response,

Compensation, and Liability Act (CERCLA or

‘‘Superfund’’). These activities include health

consultations and public health assessments

at DOE sites listed on, or proposed for, the

Superfund National Priorities List and at

sites that are the subject of petitions from the

public; and other health-related activities

such as epidemiologic studies, health

surveillance, exposure and disease registries,

health education, substance-specific applied

research, emergency response, and

preparation of toxicological profiles.

Purpose: This Subcommittee is charged

with providing advice and recommendations

to the Director, CDC and the Administrator,

ATSDR, regarding community American

Indian Tribes, and labor concerns pertaining

to CDC’s and ATSDR’s public health

activities and research at respective DOE

sites. Activities shall focus on providing a

forum for community, American Indian

Tribal, and labor interaction and serve as a

vehicle for community concern to be

expressed as advice and recommendations to

CDC and ATSDR.

Matters to be Discussed: This

Subcommittee will listen to presentations

from the Radiological Assessments

Corporation, Medical University of South

Carolina Cancer Registry, as well as updates

on the Savannah River Site Phase II Dose

Reconstruction Project findings and

implications. Additional agenda items will

include: the National Center for

Environmental Health (NCEH) activities, the

National Institute for Occupational Safety

and Health and ATSDR presentations on the

progress of current studies, and issues

regarding the Committee selection process.

Agenda items are subject to change as

priorities dictate.

Contact Persons for More Information: Paul

G. Renard or Nadine Dickerson, Radiation

Studies Branch, Division of Environmental

Hazards and Health Effects, NCEH, CDC,

4770 Buford Highway, NE, (F–35), Atlanta,

Georgia 30341–3724, telephone 770/488–

7040, FAX 770/488–7044.

Dated: December 18, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention.

[FR Doc. 95–31152 Filed 12–21–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Grassroots Regulatory Partnership

Meeting; Southwest Region; Importing

Commodities

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice of a public meeting.

SUMMARY: The Food and Drug

Administration (FDA) (Office of

Regulatory Affairs, Office of the

Southwest Region, and Office of

External Affairs) is announcing a free

public meeting to discuss ways FDA

could regulate imported commodities

more efficiently, improve levels of

communication with industries and

individuals associated with the

importation of FDA-regulated

commodities, and provide improved

levels of consumer protection in

connection with imported commodities

being shipped into the United States

across the United States-Mexico border.

This meeting is intended to identify and

evaluate opportunities for implementing

the President’s initiative for a

partnership approach between the

agency and the people affected by the

work of this agency.

DATES: The public meeting will be held

on Wednesday, January 31, 1996, from

9 a.m. to 12 m.

ADDRESSES: The public meeting will be

held at the Concourse Clarion Hotel,

Oxford Room A and B, 6789 Boeing, El

Paso, TX 79926.

FOR FURTHER INFORMATION CONTACT:

Barbara A. Cain, Food and Drug

Administration, 300 East Eight St., rm.

B123, Austin, TX 78701, 512–482–5736,

or Robert G. Rast, Food and Drug

Administration, 9777 Via De La

Amistad, rm. 128, San Diego, CA 92173,

619–661–3273.

SUPPLEMENTARY INFORMATION: There is

no registration fee for this meeting.

However, due to space limitations, early

registration is recommended. This

meeting is intended to assist importers,

brokers, and others associated with a

wide variety of products being shipped

through the southwest and west coast

(FDA Southwest and Pacific Regions).

Dated: December 15, 1995.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 95–31195 Filed 12–21–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–0403]

Drug Export; SURGISCREEN 0.8

Percent, Reagent Red Blood Cells

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Ortho Diagnostic Systems, Inc., has

filed an application requesting approval

for the export of the human biological

product SURGISCREEN 0.8 percent,

Reagent Red Blood Cells to Australia,

Austria, Belgium, Canada, Denmark,

The Federal Republic of Germany,

Finland, France, Iceland, Ireland, Italy,

Japan, Luxembourg, The Netherlands,

New Zealand, Norway, Portugal, Spain,

Sweden, Switzerland, and The United

Kingdom.

ADDRESSES: Relevant information on

this application may be directed to the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

12420 Parklawn Dr., rm. 1–23,

Rockville, MD 20857, and to the contact

person identified below. Any future

inquiries concerning the export of

human biological products under the

Drug Export Amendments Act of 1986

should also be directed to the contact

person.

FOR FURTHER INFORMATION CONTACT:

Cathy E. Conn, Center for Biologics

Evaluation and Research (HFM–610),

Food and Drug Administration, 1401

Rockville Pike,Rockville, MD 20852–

1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug

export provisions in section 802 of the

Federal Food, Drug, and Cosmetic Act

(the act) (21 U.S.C. 382) provide that

FDA may approve applications for the

export of human biological products

that are not currently approved in the

United States. Section 802(b)(3)(B) of

the act sets forth the requirements that

must be met in an application for

approval. Section 802(b)(3)(C) of the act

requires that the agency review the

application within 30 days of its filing

to determine whether the requirements

of section 802(b)(3)(B) have been

satisfied. Section 802(b)(3)(A) of the act

requires that the agency publish a notice

in the Federal Register within 10 days

of the filing of an application for export

to facilitate public participation in its
66554 Federal Register / Vol. 60, No. 246 / Friday, December 22, 1995 / Notices

review of the application. To meet this

requirement, the agency is providing

notice that Ortho Diagnostic Systems,

Inc., 1001 U.S. Highway 202, Raritan, NJ

08869–0606, has filed an application

requesting approval for the export of the

human biological product

SURGISCREEN 0.8 percent, Reagent

Red Blood Cells to Australia, Austria,

Belgium, Canada, Denmark, The Federal

Republic of Germany, Finland, France,

Iceland, Ireland, Italy, Japan,

Luxembourg, The Netherlands, New

Zealand, Norway, Portugal, Spain,

Sweden, Switzerland, and The United

Kingdom. The SURGISCREEN 0.8

percent, Reagent Red Blood Cells, is an

in vitro diagnostic test kit for the

detection of unexpected blood group

antibodies in test methods requiring a

0.8 percent red cell suspension in a low

ionic strength diluent. The application

was received and filed in the Center for

Biologics Evaluation and Research on

November 24, 1995, which shall be

considered the filing date for purposes

of the act.

Interested persons may submit

relevant information on the application

to the Dockets Management Branch

(address above) in two copies (except

that individuals may submit single

copies) and identified with the docket

number found in brackets in the

heading of this document. These

submissions may be seen in the Dockets

Management Branch between 9 a.m. and

4 p.m., Monday through Friday.

The agency encourages any person

who submits relevant information on

the application to do so by (insert date

10 days after date of publication in the

Federal Register), and to provide an

additional copy of the submission

directly to the contact person identified

above, to facilitate consideration of the

information during the 30-day review

period.

This notice is issued under the

Federal Food, Drug, and Cosmetic Act

(sec. 802 (21 U.S.C. 382)) and under

authority delegated to the Commissioner

of Food and Drugs (21 CFR 5.10) and

redelegated to the Center for Biologics

Evaluation and Research (21 CFR 5.44).

Dated: December 4, 1995.

James C. Simmons,

Director, Office of Compliance, Center for

Biologics Evaluation and Research.

[FR Doc. 95–31153 Filed 12–21–95; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

Office of the Assistant Secretary for

Community Planning and

Development

[Docket No. FR–3778–N–67]

Federal Property Suitable as Facilities

to Assist the Homeless

AGENCY: Office of the Assistant

Secretary for Community Planning and

Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies

unutilized,underutilized, excess, and

surplus Federal property reviewed by

HUD for suitability for possible use to

assist the homeless.

EFFECTIVE DATE: December 22, 1995.

FOR FURTHER INFORMATION CONTACT:

Mark Johnston, Department of Housing

and Urban Development, Room 7256,

451 Seventh Street SW, Washington, DC

20410; telephone (202) 708–1226; TDD

number for the hearing-and speechimpaired (202) 708–2565, (these

telephone numbers are not toll-free), or

call the toll-free Title V information line

at 1–800–927–7588.

SUPPLEMENTARY INFORMATION: In

accordance with the December 12, 1988

court order in National Coalition for the

Homeless v. Veterans Administration,

No. 88–2503–OG (D.D.C.), HUD

publishes a Notice, on a weekly basis,

identifying unutilized, underutilized,

excess and surplus Federal buildings

and real property that HUD has

reviewed for suitability for use to assist

the homeless. Today’s Notice is for the

purpose of announcing that no

additional properties have been

determined suitable or unsuitable this

week.

Dated: December 15, 1995.

Jacquie M. Lawing,

Deputy Assistant Secretary for Economic

Development.

[FR Doc. 95–31078 Filed 12–21–95; 8:45 am]

BILLING CODE 4210–29–M

DEPARTMENT OF THE INTERIOR

Bureau of Reclamation

[FES–95–40]

Cachuma Project Contract Renewal,

Santa Barbara County, CA

AGENCY: Bureau of Reclamation,

Interior.

ACTION: Notice of availability on the

final environmental impact statement/

final environmental impact report.

SUMMARY: Pursuant to the National

Environmental Policy Act (NEPA) of

1969 (as amended) and the California

Environmental Quality Act (CEQA), the

Bureau of Reclamation (Reclamation),

the Cachuma Project Authority

(Authority) and the Santa Barbara

County Water Agency (Agency) have

prepared a joint final environmental

impact statement/final environmental

impact report (FEIS/FEIR) for the

Cachuma Project contract renewal. The

proposed action of the lead agencies is

the continuation of the member units’

entitlement to water from the Cachuma

Project by means of a renewed water

service contract. The proposed action

exercises the provisions of several

Federal laws as applicable to

Reclamation.

ADDRESSES: Copies of the FEIS/FEIR are

available for public inspection and

review at the following locations:

• Bureau of Reclamation, Program

Analysis Office, Room 7456, 1849 C

Street NW., Washington, DC 20240;

telephone: (202) 208–4662.

• Bureau of Reclamation, Denver

Office Library, Building 67, Room 167,

Denver Federal Center, 6th and Kipling,

Denver, CO 80225; telephone: (303)

236–6963.

• Bureau of Reclamation, Regional

Director, Attention: MP–152, 2800

Cottage Way, Sacramento CA 95825–

1898; telephone: (916) 979–5129.

• Bureau of Reclamation, SouthCentral California Area Office,

Attention: SCC–412, 2666 N. Grove

Industrial Drive, Suite 106, Fresno CA

93727–1551; telephone: (209) 487–5137.

• Cachuma Project Authority, 3301

Laurel Canyon Road, Santa Barbara CA

93105–2017; telephone: (805) 569–1391.

• Santa Barbara County Water

Agency, 123 E. Anapamu Street, Santa

Barbara CA 93101–2058; telephone:

(805) 568–3542.

Libraries: Copies will also be available

for inspection at public libraries located

in Carpinteria, Montecito, Santa

Barbara, Goleta, Solvang, Buellton,

Vandenberg Village, Lompoc, and Santa

Maria, California.

FOR FURTHER INFORMATION CONTACT: Mr.

Robert May, Program Manager, SCC–

412, Bureau of Reclamation, 2666 N.

Grove Industrial Drive, Suite 106,

Fresno CA 93727–1551; telephone: (209)

487–5137; or Mr. Chris Dahlstrom,

Project Coordinator, Cachuma Project

Authority, 3301 Laurel Canyon Road,

Santa Barbara CA 93105–2017;

telephone: (805) 569–1391; or Mr.

Robert Almy, Santa Barbara County

Water Agency, 123 E. Anapamu Street,

Santa Barbara CA 93101–2058;

telephone: (805) 568–3542.